Ambroxol for the prevention of acute upper respiratory disease

Nobata, Kouichi; Fujimura, Masaki; Ishiura, Yoshiyuki; Myou, Shigeharu; Nakao, Shinji

doi:10.1007/s10238-006-0099-2

Cited by 34 publications

(25 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Antioxidant activity of ambroxol is related to the direct scavenging effect for ROS, such as superoxide anion and hydroxyl radicals [75,76]. Treatment with ambroxol also significantly decreased the incidence of acute upper respiratory diseases during winter season in humans [77].…”

Section: Ambroxolmentioning

confidence: 99%

Antioxidant Therapy as a Potential Approach to Severe Influenza-Associated Complications

2011

View full text Add to dashboard Cite

Section: Ambroxolmentioning

confidence: 99%

Antioxidant Therapy as a Potential Approach to Severe Influenza-Associated Complications

2011

View full text Add to dashboard Cite

“…Moreover, anti-influenza activity was tested for 48 of 713 agents (Table S3) [11,91,. In particular, anti-influenza activity was reported for benzbromarone, ambraxol and tannic acid [168][169][170]. Kinase inhibitors, such as dinaciclib, flavopiridol, SNS-032, and MK2206, and TNF inhibitors, such as etanercept, adalimumab and infliximab, as well as a lipid-lowering simvastatin and antibacterial vancomycin, rifampicin, and erythromycin, were also reported to possess anti-IAV activity [13,104,107,108,116,128,129,147,166,170].…”

Section: Combination Of Various Omics Techniques Identifies Potentialmentioning

confidence: 99%

Multi-Omics Studies towards Novel Modulators of Influenza A Virus-Host Interaction

Söderholm¹,

Fu²,

Gaelings³

et al. 2016

Preprint

View full text Add to dashboard Cite

Human influenza A viruses (IAVs) cause global pandemics and epidemics. These viruses evolve rapidly, making current treatment options ineffective. To identify novel modulators of IAV-host interactions, we re-analyzed our recent transcriptomics, metabolomics, proteomics, phosphoproteomics, and genomics/virtual ligand screening data. We identified 713 potential modulators targeting 199 cellular and two viral proteins. Anti-influenza activity for 48 of them has been reported previously, whereas the antiviral efficacy of the 665 remains unknown. Studying anti-influenza efficacy and immuno/neuro-modulating properties of these compounds and their combinations as well as potential viral and host resistance to them may lead to the discovery of novel modulators of IAV-host interactions, which might be more effective than the currently available anti-influenza therapeutics.

show abstract

“…There are only limited data that mucolytics provide any benefit in chronic pulmonary disease, and in this condition their efficacy is assessed over months rather than weeks or days [67,68]. There is no clinical data to support the efficacy of mucolytics as expectorants in acute respiratory infections such as common cold but one study does indicate that ambroxol may help to prevent colds [69].…”

Section: Mucolyticsmentioning

confidence: 99%

Over the counter medicines for colds

Eccles

2009

Commond Cold

View full text Add to dashboard Cite

Over the counter (OTC) medicines may be defined as medicines that are freely available to the public without a prescription from a doctor. Self-medication for common cold is now encouraged by most government health authorities in order not to overload health resources in winter. This chapter examines the efficacy of the different groups of medicines for the relief of common cold symptoms (analgesics, decongestants, antihistamines, antitussives, menthol, expectorants and mucolytics, throat lozenges and sprays, multisymptom products, and hot drinks). Safety is the most important factor in any common cold medicine because of the widespread use of the medicines. Because of limitations in dose due to safety concerns many OTC medicines are used at the limits of efficacy and there is often little clinical data to support efficacy, and safety is often supported from a long history of safe use. Aspirin, paracetamol and ibuprofen are the most widely used analgesic treatments to alleviate pain and fever both as monotherapies and in combination with other cold medicines and their efficacy and safety is supported by data from trials on other pain models. The efficacy of nasal decongestants can be supported by clinical trials, and similarly the symptom relief provided by menthol for nasal congestion. The efficacy data for antihistamines, and antitussives is limited and controversial, and there is no real clinical support for the efficacy of expectorants and mucolytics. There is no doubt that all of the OTC common cold medicines are popular with consumers and that they do provide relief from symptoms that in some cases may be more due to a placebo effect than a pharmacological effect of an active ingredient. Multi-symptom medicines provide a safe and convenient way of treating the common cold syndrome of multiple symptoms but their use is sometimes criticised when not all symptoms need to be treated. Hot drinks can provide immediate and sustained relief from symptoms, especially cough and sore throat.

show abstract

Ambroxol for the prevention of acute upper respiratory disease

Cited by 34 publications

References 13 publications

Antioxidant Therapy as a Potential Approach to Severe Influenza-Associated Complications

Antioxidant Therapy as a Potential Approach to Severe Influenza-Associated Complications

Multi-Omics Studies towards Novel Modulators of Influenza A Virus-Host Interaction

Over the counter medicines for colds

Contact Info

Product

Resources

About